Outcomes in patients undergoing cardiac surgery who decline transfusion and received erythropoietin compared to patients who did not: A matched cohort study

Anesthesia and Analgesia

Volumn 127, Issue 2, 2018, Pages 490-495

  Duce, Lorent ^a   Cooter, Mary L ^b   McCartney, Sharon L ^b   Lombard, Frederick W ^b,c   Guinn, Nicole R ^b,d  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATININE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ERYTHROPOIETIN; HEMOGLOBIN; PADGEM PROTEIN; ANTIANEMIC AGENT; EPO PROTEIN, HUMAN;

ACUTE KIDNEY FAILURE; AGED; ANEMIA; ARTICLE; ATRIAL FIBRILLATION; BLOOD TRANSFUSION; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; ERYTHROCYTE TRANSFUSION; EUROSCORE; EXTUBATION; FEMALE; HEART SURGERY; HEART TRANSPLANTATION; HEART VALVE SURGERY; HOSPITAL MORTALITY; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THORACIC AORTIC SURGERY; TREATMENT OUTCOME; WOUND INFECTION; ALGORITHM; COMPARATIVE STUDY; HOSPITAL DISCHARGE; JEHOVAH'S WITNESS; MIDDLE AGED; PREOPERATIVE PERIOD; PROCEDURES; RISK; SEVERITY OF ILLNESS INDEX; TREATMENT REFUSAL;

AGED; ALGORITHMS; ANEMIA; BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; JEHOVAH'S WITNESSES; LENGTH OF STAY; MALE; MIDDLE AGED; PATIENT DISCHARGE; PREOPERATIVE PERIOD; RETROSPECTIVE STUDIES; RISK; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 85054745662     PISSN: 00032999     EISSN: 15267598     Source Type: Journal    
DOI: 10.1213/ANE.0000000000002418     Document Type: Article

References (31)

1. Watch Tower Bible & Tract Society. Keep Yourself in God's Love. Wallkill, NY: Watch Tower Bible and Tract Society of Pennsylvania Publishers; 2014:215-218.
2. McQuilten ZK, Andrianopoulos N, Wood EM, et al. Transfusion practice varies widely in cardiac surgery: results from a national registry. J Thorac Cardiovasc Surg. 2014;147:1684-1690.e1.
3. Musallam KM, Tamim HM, Richards T, et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet. 2011;378:1396-1407.
4. Musallam KM, Jamali FR, Rosendaal FR, et al. Preoperative hematocrit concentration and the risk of stroke in patients undergoing isolated coronary-artery bypass grafting. Anemia. 2013;2013:206829.
5. Bhaskar B, Dulhunty J, Mullany DV, Fraser JF. Impact of blood product transfusion on short and long-term survival after cardiac surgery: more evidence. Ann Thorac Surg. 2012;94:460-467.
6. Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood. 2009;113:3406-3417.
7. Shaw RE, Johnson CK, Ferrari G, et al. Blood transfusion in cardiac surgery does increase the risk of 5-year mortality: results from a contemporary series of 1714 propensity-matched patients. Transfusion. 2014;54:1106-1113.
8. Galas FR, Almeida JP, Fukushima JT, et al. Blood transfusion in cardiac surgery is a risk factor for increased hospital length of stay in adult patients. J Cardiothorac Surg. 2013;8:54.
9. Patient Blood Management Programs. Society for the Advancement of Blood Management web site. Available at: https://www.sabm.org/patient-blood-management-programs. Accessed March 20, 2017.
10. Memorial Commemoration. 2016 Yearbook of Jehovah's Witnesses. Wallkill, NY: Watchtower Bible And Tract Society Of New York, Inc; 2016:117. Available at: https://downloada. akamaihd.net/files/media-books/ca/yb16-E.pdf. Accessed March 20, 2017.
11. Ott DA, Cooley DA. Cardiovascular surgery in Jehovah's Witnesses. Report of 542 operations without blood transfusion. JAMA. 1977;238:1256-1258.
12. Jelkmann W. Regulation of erythropoietin production. J Physiol. 2011;589:1251-1258.
13. Tran DH, Wong GT, Chee YE, Irwin MG. Effectiveness and safety of erythropoiesis-stimulating agent use in the perioperative period. Expert Opin Biol Ther. 2014;14:51-61.
14. McKoy JM, Stonecash RE, Cournoyer D, et al. Epoetinassociated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008;48:1754-1762.
15. US Food and Drug Administration. PROCRIT® (Epoetin alfa) FOR INJECTION. Available at: https://www.accessdata. fda.gov/drugsatfda-docs/label/2010/103234s5199lbl.pdf. Accessed March 20, 2017.
16. Bergstralh, E, Jon K. Vmatch macro. Mayo Clinic, published April 2014. Available at: http://www.mayo.edu/research/departments-divisions/department-health-sciences-research/division-biomedical-statistics-informatics/software/locallywritten-sas-macros. Accessed June 30, 2015.
17. McCartney S, Guinn N, Roberson R, Broomer B, White W, Hill S. Jehovah's Witnesses and cardiac surgery: a single institution's experience. Transfusion. 2014;54:2745-2752.
18. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-590.
19. Singh AK, Szczech L, Tang KL, et al; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-2098.
20. US Food and Drug Administration. Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)]. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm126481.htm. Accessed March 20, 2017.
21. Berridge MV, Fraser JK, Carter JM, Lin FK. Effects of recombinant human erythropoietin on megakaryocytes and on platelet production in the rat. Blood. 1988;72:970-977.
22. Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood. 2000;95:2983-2989.
23. Beguin Y. Erythropoietin and platelet production. Haematologica. 1999;84:541-547.
24. Cases A, Escolar G, Reverter JC, et al. Recombinant human erythropoietin treatment improves platelet function in uremic patients. Kidney Int. 1992;42:668-672.
25. Marinakis S, Van der Linden P, Tortora R, Massaut J, Pierrakos C, Wauthy P. Outcomes from cardiac surgery in Jehovah's witness patients: experience over twenty-one years. J Cardiothorac Surg. 2016;11:67.
26. Yoo YC, Shim JK, Kim JC, Jo YY, Lee JH, Kwak YL. Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. Anesthesiology. 2011;115:929-937.
27. Cladellas M, Farré N, Comín-Colet J, et al. Effects of preoperative intravenous erythropoietin plus iron on outcome in anemic patients after cardiac valve replacement. Am J Cardiol. 2012;110:1021-1026.
28. Lin DM, Lin ES, Tran MH. Efficacy and safety of erythropoietin and intravenous iron in perioperative blood management: a systematic review. Transfus Med Rev. 2013;27:221-234.
29. D'Ambra MN, Gray RJ, Hillman R, et al. Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. Ann Thorac Surg. 1997;64:1686-1693.
30. Pattakos G, Koch CG, Brizzio ME, et al. Outcome of patients who refuse transfusion after cardiac surgery: a natural experiment with severe blood conservation. Arch Intern Med. 2012;172:1154-1160.
31. Guinn NR, Roberson RS, White W, et al. Costs and outcomes after cardiac surgery in patients refusing transfusion compared with those who do not: a case-matched study. Transfusion. 2015;55:2791-2798.